| Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate L Bunse, S Pusch, T Bunse, F Sahm, K Sanghvi, M Friedrich, D Alansary, ... Nature medicine 24 (8), 1192-1203, 2018 | 493 | 2018 |
| ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma C Zhang, MC Burger, L Jennewein, S Genßler, K Schönfeld, P Zeiner, ... Journal of the National Cancer Institute 108 (5), djv375, 2016 | 398 | 2016 |
| CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy MC Burger, C Zhang, PN Harter, A Romanski, F Strassheimer, C Senft, ... Frontiers in immunology 10, 2683, 2019 | 203 | 2019 |
| Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor … S Genßler, MC Burger, C Zhang, S Oelsner, I Mildenberger, M Wagner, ... Oncoimmunology 5 (4), e1119354, 2016 | 193 | 2016 |
| Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic–induced apoptosis P Antonietti, B Linder, S Hehlgans, IC Mildenberger, MC Burger, S Fulda, ... Molecular cancer therapeutics 16 (1), 156-168, 2017 | 86 | 2017 |
| Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine KJ Wenger, M Wagner, SJ You, K Franz, PN Harter, MC Burger, M Voss, ... Oncology letters 14 (1), 1141-1146, 2017 | 73 | 2017 |
| Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease MC Burger, MW Ronellenfitsch, NI Lorenz, M Wagner, M Voss, D Capper, ... Oncology reports 38 (6), 3291-3296, 2017 | 67 | 2017 |
| Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells … MW Ronellenfitsch, DP Brucker, MC Burger, S Wolking, F Tritschler, ... Brain 132 (6), 1509-1522, 2009 | 65 | 2009 |
| Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors A Wick, O Bähr, M Schuler, K Rohrberg, SP Chawla, F Janku, D Schiff, ... Clinical cancer research 27 (10), 2723-2733, 2021 | 53 | 2021 |
| Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma MC Burger, MT Forster, A Romanski, F Straßheimer, J Macas, PS Zeiner, ... Neuro-oncology 25 (11), 2058-2071, 2023 | 52 | 2023 |
| Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas L Jennewein, MW Ronellenfitsch, P Antonietti, EI Ilina, J Jung, D Stadel, ... Oncotarget 7 (15), 20016, 2016 | 38 | 2016 |
| Immunohistochemical assessment of phosphorylated mTORC1-pathway proteins in human brain tumors PN Harter, L Jennewein, P Baumgarten, E Ilina, MC Burger, AL Thiepold, ... PloS one 10 (5), e0127123, 2015 | 27 | 2015 |
| Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells I Bruns, B Sauer, MC Burger, J Eriksson, U Hofmann, Y Braun, PN Harter, ... Journal of Biological Chemistry 294 (9), 3037-3050, 2019 | 25 | 2019 |
| AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma MI Strecker, K Wlotzka, F Strassheimer, B Roller, G Ludmirski, S König, ... Oncoimmunology 11 (1), 2127508, 2022 | 24 | 2022 |
| Calcitriol promotes differentiation of glioma stem-like cells and increases their susceptibility to temozolomide J Gerstmeier, AL Possmayer, S Bozkurt, ME Hoffmann, I Dikic, ... Cancers 13 (14), 3577, 2021 | 22 | 2021 |
| Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial T Zeyen, AL Potthoff, R Nemeth, DH Heiland, MC Burger, JP Steinbach, ... Trials 23 (1), 57, 2022 | 20 | 2022 |
| AMPK activation protects astrocytes from hypoxia-induced cell death L Barialai, MI Strecker, AL Luger, M Jäger, I Bruns, ACM Sittig, ... International journal of molecular medicine 45 (5), 1385-1396, 2020 | 20 | 2020 |
| Bevacizumab for patients with recurrent multifocal glioblastomas MC Burger, S Breuer, HC Cieplik, PN Harter, K Franz, O Bähr, ... International journal of molecular sciences 18 (11), 2469, 2017 | 20 | 2017 |
| PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma MC Burger, DP Brucker, P Baumgarten, MW Ronellenfitsch, C Wanka, ... International journal of oncology 41 (1), 235-241, 2012 | 18 | 2012 |
| Addition of anti-angiogenetic therapy with bevacizumab to chemo-and radiotherapy for leptomeningeal metastases in primary brain tumors MC Burger, PS Zeiner, K Jahnke, M Wagner, M Mittelbronn, JP Steinbach PLoS One 11 (6), e0155315, 2016 | 17 | 2016 |
